β2-Adrenergic Agonists for Parkinson’s Disease: Repurposing Drugs at the Crossroad of the Brain and the Immune System
Commentary On the study by Mittal S, Science, 2017; 357(6354):891-898. doi: 10.1126/science.aaf3934 β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease Parkinson’s disease (PD) affects 0.1-0.2% of the general population with increasing prevalence with age, and up to 1% in individuals above 60 years of age, resulting in an estimated 7 […]
Massachusetts Neuroscience Consortium: A Collaborative Model between Government, Academia and Industry
Laboratories in academia and industry often work independently, but recently, a coalition of academic researchers, pharmaceutical companies and state governments announced the formation of the Massachusetts Neuroscience Consortium. The $1.75 million partnership intends to fundamentally shift the neurological disease research. Founders of this new project recognized that a highly collaborative and coordinated effort must be […]
Parkinson’s Disease: Peripheral Immunity Links Neurodegeneration and the Intestinal Microbiota
Posted on August 24, 2019 By Marco Cosentino Commentaries
Commentary By Marco Cosentino, Cristoforo Comi and Franca Marino On the study by Matheoud D et al., Nature, 2019; 571(7766):565-569; Doi: 10.1038/s41586-019-1405-y, Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1-/- mice. Parkinson’s disease (PD) is a chronic neurodegenerative disease affecting 7 to 10 million people worldwide, 1% above 60 years of age and up to […]